NICE endorses alitretinoin use

Patients with severe chronic hand eczema who have run out of treatment options can now be considered for treatment with alitretinoin (Toctino), according to new guidance issued by NICE.

Alitretinoin, an orally administered retinoid, is recommended for adults whose disease has not responded to potent topical corticosteroids. Eligible patients must also have a dermatology life quality index (DLQI) score of 15 or more.

Treatment with alitretinoin should be stopped:

  • when an adequate response (hands clear or almost clear) is achieved.
  • if eczema remains severe after 12 weeks.
  • if an adequate response is not achieved by 24 weeks.

Disease is considered ‘severe' if defined as such by the physician's global assessment (PGA).

Only physicians who are experienced in both the management of severe chronic hand eczema and the use of systemic retinoids should start and monitor treatment with alitretinoin.

View Toctino drug record

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Calcium and Vitamin D Supplements for Osteoporosis

Calcium and Vitamin D Supplements for Osteoporosis

Formulations, doses and costs of osteoporosis supplements.

Asthma and COPD Preparations and Compatible Devices

Asthma and COPD Preparations and Compatible Devices

Available presentations of bronchodilators and anti-inflammatories.

Topical Steroids, Comparison of Potencies and Formulations

Topical Steroids, Comparison of Potencies and Formulations

Strengths and formulations of topical steroids.

Topical Steroids, Potential Skin Sensitisers as Ingredients

Topical Steroids, Potential Skin Sensitisers as Ingredients

Potential sensitising agents in topical steroids.